Cargando…
High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab
BACKGROUND: The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended in international guidelines. In these cases,...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665689/ https://www.ncbi.nlm.nih.gov/pubmed/34938439 http://dx.doi.org/10.1002/clt2.12085 |